SMAD2 and neoplasm: Moreover, treatment with SIS3, a specific SMAD3 inhibitor, significantly improved CD107a expression in CD56dim tumor-infiltrating NK cells (TINKs)—a subset where we observed increased SMAD2–3 phosphorylation compared to their liver-resident counterparts.